Search details
1.
Pembrolizumab for the treatment of non-small-cell lung cancer.
N Engl J Med
; 372(21): 2018-28, 2015 May 21.
Article
in English
| MEDLINE | ID: mdl-25891174
2.
Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial.
Lancet
; 387(10027): 1540-1550, 2016 Apr 09.
Article
in English
| MEDLINE | ID: mdl-26712084
3.
The F box protein Fbx6 regulates Chk1 stability and cellular sensitivity to replication stress.
Mol Cell
; 35(4): 442-53, 2009 Aug 28.
Article
in English
| MEDLINE | ID: mdl-19716789
4.
Computational and bioinformatics frameworks for next-generation whole exome and genome sequencing.
ScientificWorldJournal
; 2013: 730210, 2013.
Article
in English
| MEDLINE | ID: mdl-23365548
5.
Quantitative in situ analysis of beta-catenin expression in breast cancer shows decreased expression is associated with poor outcome.
Cancer Res
; 66(10): 5487-94, 2006 May 15.
Article
in English
| MEDLINE | ID: mdl-16707478
6.
Retrospective Molecular Epidemiology Study of PD-L1 Expression in Patients with EGFR-Mutant Non-small Cell Lung Cancer.
Cancer Res Treat
; 50(1): 95-102, 2018 Jan.
Article
in English
| MEDLINE | ID: mdl-28301925
7.
Classification of breast cancer using genetic algorithms and tissue microarrays.
Clin Cancer Res
; 12(21): 6459-68, 2006 Nov 01.
Article
in English
| MEDLINE | ID: mdl-17085660
8.
Programmed Death Ligand 1 Expression in Paired Non-Small Cell Lung Cancer Tumor Samples.
Clin Lung Cancer
; 18(6): e473-e479, 2017 11.
Article
in English
| MEDLINE | ID: mdl-28669849
9.
Quantitative analysis of breast cancer tissue microarrays shows that both high and normal levels of HER2 expression are associated with poor outcome.
Cancer Res
; 63(7): 1445-8, 2003 Apr 01.
Article
in English
| MEDLINE | ID: mdl-12670887
10.
Automated quantitative analysis of tissue microarrays reveals an association between high Bcl-2 expression and improved outcome in melanoma.
Cancer Res
; 64(23): 8773-7, 2004 Dec 01.
Article
in English
| MEDLINE | ID: mdl-15574790
11.
Tissue microarray analysis of hepatocyte growth factor/Met pathway components reveals a role for Met, matriptase, and hepatocyte growth factor activator inhibitor 1 in the progression of node-negative breast cancer.
Cancer Res
; 63(5): 1101-5, 2003 Mar 01.
Article
in English
| MEDLINE | ID: mdl-12615728
12.
Development of a Companion Diagnostic PD-L1 Immunohistochemistry Assay for Pembrolizumab Therapy in Non-Small-cell Lung Cancer.
Appl Immunohistochem Mol Morphol
; 24(6): 392-7, 2016 Jul.
Article
in English
| MEDLINE | ID: mdl-27333219
13.
[Letter to the Editor] The need for improved education and training in research antibody usage and validation practices.
Biotechniques
; 61(1): 16-8, 2016.
Article
in English
| MEDLINE | ID: mdl-27401669
14.
PD-L1 Expression and Survival among Patients with Advanced Non-Small Cell Lung Cancer Treated with Chemotherapy.
Transl Oncol
; 9(1): 64-69, 2016 Feb.
Article
in English
| MEDLINE | ID: mdl-26947883
15.
Development of a Prototype Immunohistochemistry Assay to Measure Programmed Death Ligand-1 Expression in Tumor Tissue.
Arch Pathol Lab Med
; 140(11): 1259-1266, 2016 Nov.
Article
in English
| MEDLINE | ID: mdl-27788043
16.
Development of a Companion Diagnostic for Pembrolizumab in Non-Small Cell Lung Cancer Using Immunohistochemistry for Programmed Death Ligand-1.
Arch Pathol Lab Med
; 140(11): 1243-1249, 2016 11.
Article
in English
| MEDLINE | ID: mdl-27552095
17.
Prognostic Significance of PD-L1 in Patients with Non-Small Cell Lung Cancer: A Large Cohort Study of Surgically Resected Cases.
J Thorac Oncol
; 11(7): 1003-11, 2016 07.
Article
in English
| MEDLINE | ID: mdl-27103510
18.
Programmed Death-Ligand 1 Expression and Response to the Anti-Programmed Death 1 Antibody Pembrolizumab in Melanoma.
J Clin Oncol
; 34(34): 4102-4109, 2016 12.
Article
in English
| MEDLINE | ID: mdl-27863197
19.
Antitumor Activity of Pembrolizumab in Biomarker-Unselected Patients With Recurrent and/or Metastatic Head and Neck Squamous Cell Carcinoma: Results From the Phase Ib KEYNOTE-012 Expansion Cohort.
J Clin Oncol
; 34(32): 3838-3845, 2016 11 10.
Article
in English
| MEDLINE | ID: mdl-27646946
20.
X-tile: a new bio-informatics tool for biomarker assessment and outcome-based cut-point optimization.
Clin Cancer Res
; 10(21): 7252-9, 2004 Nov 01.
Article
in English
| MEDLINE | ID: mdl-15534099